Comparative evaluation of surfactant and hydrophobizing agent concentration in relation to the optimal particle size of metered-dose inhalers

Drug Development and Industrial Pharmacy

Volumn 24, Issue 9, 1998, Pages 853-856

  Fedina, L T ^a   Zelko R ^b   Fedina, L I ^c   Szabados, Zs ^a   Szanto M ^a  

^a EG/S Pharmaceuticals Ltd   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c Schopf Merei Agost Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM; OLEIC ACID; SURFACTANT;

AEROSOL; ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; MATHEMATICAL MODEL; METERED DOSE INHALER; PARTICLE SIZE;

EID: 0031709284     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049809088530     Document Type: Article

References (10)

1. P. R. Byron, Drug Dev. Ind. Pharm., 12, 993 (1986).
2. P. R. Byron, Pharm. Technol., 11, 42 (1987).
3. A. Adjei and J. Garren, Pharm. Res., 7, 565 (1990).
4. S. S. Davis and M. D. Bubb, Int. J. Pharm., 1, 303 (1978).
5. J. G. Clarke, S. R. Wicks, and S. J. Farr, Int. J. Pharm., 93, 221 (1993).
6. C. Bower, C. Washington, and T. S. Purewal, Int. J. Pharm., 118, 229 (1995).
7. C. Bower, C. Washington, and T. S. Purewal, J. Pharm. Pharmacol., 48, 337 (1996).
8. C. Bower, C. Washington, and T. S. Purewal, J. Pharm. Pharmacol., 48, 342 (1996).
9. R. M. Franz, J. E. Browne, and A. R. Lewis, Experimental Design Modeling, and Optimization Strategies for Product and Process Development, Marcel Dekker Inc., New York, 1988.
10. R. J. Pugh, T. Matsunaga, and F. M. Fowkes, Colloid Surf., 7, 183 (1983).